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Abstract
Background:  Increased serum remnant lipoproteins are supposed to predict cardiovascular
disease in addition to increased LDL. A new homogenous assay for remnant lipoprotein-
cholesterol (RemL-C) has been developed as an alternative to remnant-like particle-cholesterol
(RLP-C), an immunoseparation assay, widely used for the measurement of remnant lipoprotein
cholesterol.
Methods: We evaluated the correlations and data validation between the 2 assays in 83 subjects
(49 men and 34 women) without diabetes, hypertension and medications for hyperlipidemia,
diabetes, and hypertension, and investigated the characteristics of remnant lipoproteins obtained
by the two methods (RLP-C and RemL-C) and their relationships with IDL-cholesterol determined
by our developed HPLC method.
Results: A positive correlation was significantly found between the two methods (r = 0.853, 95%CI
0.781–0.903, p < 0.0001). Bland & Altman analysis revealed that RemL-C values were likely to be
significantly higher than RLP-C values, particularly in samples with high levels of remnant
lipoproteins. Several data dissociations between the RemL-C and RLP-C were also observed. The
HPLC chromatograms show high concentrations of chylomicron cholesterol in serum samples with
RemL-C level < RLP-C level, but high concentrations of IDL-cholesterol in samples with RemL-C
level > RLP-C level. RemL-C (r = 0.339, 95%CI 0.152–0.903; p = 0.0005) significantly correlated
with IDL-cholesterol, but not RLP-C (r = 0.17, 95%CI -0.047–0.372; p = 0.1237) in all the samples
(n = 83).
Conclusion: These results suggest that there is generally a significant correlation between RemL-
C and RLP-C. However, RemL-C assay is likely to reflect IDL more closely than RLP-C.
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Background
Hypertriglyceridemia is a heterogeneous disorder of lipo-
protein metabolism with a less definite association to
atherosclerosis risk than hypercholesterolemia or
increased low-density lipoprotein (LDL)-cholesterol [1].
Patients with moderate hypertriglyceridemia such as
familial combined hyperlipidemia, diabetic dyslipidemia,
or metabolic syndrome more often develop premature
atherosclerotic diseases, because smaller-sized triglyceride
(TG)-rich lipoproteins such as chylomicron remnants and
very-low-density lipoprotein (VLDL) remnants penetrate
the arterial intima from plasma, than larger-sized chylom-
icrons [1-6]. Remnant lipoproteins are atherogenic, and
elevated remnant lipoproteins are associated with the
increased risk of cardiovascular disease [2-8].
Two clinically available methods to determine cholesterol
levels of remnant lipoproteins have ever been developed,
but these assay procedures are basically different. First,
remnant-like particle-cholesterol (RLP-C), an immunoaf-
finity separation method (RLP-C assay; Otsuka, Japan)
was developed, and this assay isolates remnant-like parti-
cles (RLPs) from human serum using an immunoaffinity
gel containing two different immobilized monoclonal
antibodies to human apolipoproteins A-1 and B-100
[9,10]. Many clinical studies have demonstrated that RLP-
C is a risk factor for cardiovascular disease, and serum
RLP-C levels are higher in patients with coronary artery
disease, diabetes, and metabolic syndrome than in
healthy subjects [2,4,11]. Thus, RLP-C measurement can
be performed without an ultracentrifugation, but it takes
some time and is not able to be run on an autoanalyzer.
Next, Remnant Lipoprotein Cholesterol Homogenous
assay (RemL-C assay; Kyowa Medex, Japan) was devel-
oped, and this assay utilizes special surfactant [polyox-
yethylene-polyoxybutylene (POE-POB) block copolymer]
and phospholipase D, which can selectively solubilize
and degrade TG-rich remnant lipoproteins, VLDL rem-
nants and chylomicron remnants [12,13]. In contrast to
RLP-C assay, RemL-C assay is able to be performable on a
universal autoanalyzer, thereby allowing quick and high
throughput measurements. Nakada et al [13] reported
that remnant lipoproteins, measured by RemL-C, were
increased in patients with coronary artery disease, indicat-
ing the clinical significance of coronary risk assessment by
remnant lipoprotein levels measured by RemL-C. In sam-
ples from patients with diabetes, RemL-C correlated with
RLP-C, but discrepant data between the 2 methods were
found investigated by the gel filtration method, suggest-
ing a murky difference in the affinity of respective assay
reagents to various TG-rich lipoproteins [12].
We developed a novel high performance liquid chroma-
tography (HPLC) method for measuring cholesterol levels
in the major classes of serum lipoproteins within 25 min
using an anion exchange column filled with diethylami-
noethyl-ligand nonporous polymer-based gel by elution
with a step gradient of sodium perchlorate concentration
[14,15]. This HPLC method is able to determine choles-
terol levels of HDL, LDL, IDL (intermediate-density lipo-
protein), VLDL, and chylomicron similarly to the
ultracentrifugation method, a golden standard method to
determine cholesterol levels of lipoprotein fractions
despite its the technical complexity inappropriate for rou-
tine clinical laboratory use. Cholesterol values of HDL,
LDL, IDL, VLDL and chylomicron measured by this HPLC
method are correlated to those estimated by the ultracen-
trifugation method [14], and therefore this HPLC method
may be employed as a substitute of the ultracentrifugation
method. RLP-C correlated well with VLDL-cholesterol but
poorly with IDL-cholesterol, measured by the HPLC
method [14] similarly as RLP-C was correlated to VLDL-
cholesterol but not to IDL-cholesterol, measured by the
ultracentrifugation method [10]. However, the associa-
tions of RemL-C with VLDL and IDL have never been
examined quantitatively by the HPLC method, although
the RemL-C values contain VLDL remnant (IDL) choles-
terol concentrations qualitatively estimated by the gel fil-
tration method and polyacrylamide gel electrophoresis
analysis in the previous report [12].
In the context, we evaluated the correlations and data val-
idation between the 2 assays (RLP-C and RemL-C) in sub-
jects without diabetes, hypertension and medications for
hyperlipidemia, diabetes, and hypertension, and investi-
gated the characteristics of remnant lipoproteins obtained
by the two assays and their relationships with IDL-choles-
terol determined quantitatively by our HPLC method.
Methods
Specimens
We tested 83 clinical samples of fasting sera consecutively
obtained from patients (49 men and 34 women), aged 61
± 10 years, without diabetes, hypertension and medica-
tions for hyperlipidemia, diabetes, and hypertension at
outpatient clinics of Jikei University Hospital, Japan. Fast-
ing samples were used in the present study because dietary
fats may influence postprandial lipoprotein status, but
fasting states in the study subjects were not necessarily
completed for more than 12 hours. All subjects gave
informed consent to participate in the present study. This
study protocols were approved by the ethics committee of
Jikei University School of Medicine. Blood samples were
allowed to clot at room temperature and immediately
were centrifuged at 2000 × g for 15 minutes to prepare
serum samples. All serum samples were analyzed immedi-
ately after serum preparation.Lipids in Health and Disease 2008, 7:18 http://www.lipidworld.com/content/7/1/18
Page 3 of 5
(page number not for citation purposes)
Determination of cholesterol concentrations of remnant 
lipoproteins
Cholesterol concentrations of remnant lipoproteins were
measured by the RLP-C assay (Otsuka, Japan) and the
RemL-C assay (Kyowa Medex, Japan).
RLP-C assay isolates remnant-like particles (RLPs) from
human serum using an immunoaffinity gel containing
two different immobilized monoclonal antibodies to
human apolipoprotein A-1 (H-12) and B-100 (JI-H)
[9,10]. RLP-C assay was performed according to manufac-
turer's procedures. Briefly, a-3 mm diameter stainless steel
bead (Otsuka, Electronics) was added to each micro sam-
ple cup (Boehringer Mannheim); 300 μl of the immu-
noaffinity gel and 5 μl of specimen were then added to
each cup, and the mixture was incubated at room temper-
ature on a mixer with build-in magnetic bars to suffi-
ciently mix by driving the beads up and down in each cup.
After 2 hour, the supernatant (unbound fraction) was
transferred for cholesterol quantification by an enzymatic
assay. The cholesterol values were multiplied 61-fold to
reflect dilution of the specimen at the immunoseparation
step.
RemL-C assay utilizes surfactant POE-POB block copoly-
mer and phospholipase D, which can selectively solubi-
lize and degrade TG-rich remnant lipoproteins, VLDL
remnants and chylomicron remnants [12,13]. Then,
released cholesterol was measured enzymatically. POE-
POB selectively binds to VLDL remnants and IDL parti-
cles, and the phospholipase D addition supports the reac-
tivity towards chylomicron remnants. This RemL-C assay
was performed with a universal autoanalyzer (Hitachi
7600 automated analyzer, Japan).
Determination of IDL cholesterol and lipoprotein profile 
by the HPLC method
Cholesterol levels of fractionated lipoproteins were meas-
ured by our developed HPLC method [14,15]. Briefly,
serum lipoproteins were separated on a column contain-
ing diethylaminoethyl- ligand nonporous polymer-based
gel by elution with a step gradient of sodium perchlorate
concentration, and cholesterol concentrations of fraction-
ated lipoproteins were measured by a post-column reac-
tion with a reagent containing cholesterol esterase and
cholesterol oxidase. HDL, LDL, IDL, VLDL and chylomi-
cron were separated in this order within 25 minutes, and
cholesterol levels of these lipoproteins were measured
enzymatically.
Statistics
For the comparison study, linear regression analyses
between the two methods (RLP-C assay and RemL-C
assay) were analyzed by Pearson product-moment corre-
lation test. The correlations of RLP-C or RemL-C values to
IDL cholesterol levels, measured by the HPLC method,
were also analyzed. In addition, Bland & Altman method
was used to perform the concordance analysis between
RLP-C values and RemL-C values. This analysis graph dis-
plays a scatter diagram of the differences plotted against
the averages of the two measurements. The upper and
lower limits of concordance were calculated as the mean
difference plus/minus 1.96 times standard deviation
(SD). A value of p < 0.05 was considered statistically sig-
nificant.
Results and Discussion
First, we evaluated the correlation of remnant lipoprotein
cholesterol concentrations between RemL-C and RLP-C
assay. A positive correlation (r = 0.853, 95%CI 0.781–
0.903, p < 0.0001) was significantly found between the
two methods as shown in Figure 1, while value dissocia-
tions between the two methods were also observed in sev-
eral samples. As shown in Figure 2, the Bland & Altman
analysis between RemL-C and RLP-C showed a significant
mean difference (1.48 ± 2.67, 95%CI 0.9–2.07) and a sig-
nificant proportional error (r = 0.558, p < 0.0001).
Namely, RemL-C values are likely to be significantly
higher than RLP-C values, observed particularly in sam-
ples with high levels of remnant lipoproteins.
Next, we investigated the lipoprotein profiles of these
data-mismatched samples by using the HPLC method to
find out the lipoprotein details with regard to the data dis-
crepancies between the two methods. Serum samples with
RemL-C value < RLP-C value showed high concentrations
of chylomicron cholesterol, while samples with RemL-C
value > RLP-C value showed high concentrations of IDL-
Correlation between RemL-C and RLP-C values Figure 1
Correlation between RemL-C and RLP-C values. 
Arrows indicate value dissociations of remnant lipoprotein 
cholesterol level between RemL-C assay and RLP-C assay.
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cholesterol, as shown in Figure 3 which demonstrates the
representative HPLC chromatograms, indicated by arrows
in Figure 1, in such dissociated samples. In all the samples
(n = 83), RemL-C values (r = 0.339, 95%CI 0.152–0.903,
p = 0.0005) significantly correlated with IDL-cholesterol
concentrations but RLP-C values did not (r = 0.17, 95%CI
-0.047–0.372, p = 0.1237). Therefore, RemL-C is likely to
be more closely associated with IDL-cholesterol than RLP-
C. However, RLP-C might be associated with large-sized
TG-rich lipoproteins such as chylomicron and chylomi-
cron remnants in contrast to the close association of
RemL-C to IDL. HPLC lipoprotein analysis data showed
significant correlations of RemL-C and RLP-C to VLDL-
cholesterol [r = 0.538 (p < 0.0001) and r = 0.382 (p =
0.0003), respectively] and chylomicron-cholesterol [r =
0.501 (p < 0.0001) and r = 0.383 (p = 0.0003), respec-
tively). Thus, such similar trends in correlations of rem-
nant lipoprotein cholesterol to VLDL and chylomicron
were found in the both methods.
The present study was performed to compare the charac-
teristics of the RemL-C (homogenous assay) and RLP-C
(immunoseparation assay) for the measurement of cho-
lesterol levels of TG-rich remnant lipoproteins. The signif-
icant correlations between the two methods (RemL-C and
RLP-C) have been reported in general samples, while dis-
crepancies between them were also observed particularly
in cases with increased IDL, qualitatively estimated, in
patients with diabetes [12]. Previous papers have reported
that RLP particles are little resemble to classical VLDL rem-
nants, which is smaller than nascent VLDL particles and
not enriched in apolipoprotein E relative to apolipopro-
tein Cs. In addition, Leary et al. reported a high associa-
tion between buoyant VLDL-cholesterol and RLP-C values
but a modest association between IDL-cholesterol and
RLP-C [10]. In the present study, the HPLC lipoprotein
analysis also showed no significant association between
RLP-C and IDL-cholesterol. The quantitative analysis by
the HPLC assay shows that RLP-C values are likely to
poorly reflect smaller-sized TG-rich lipoprotein remnants
such as IDL particles.
In the RemL-C method, POE-POB, a special surfactant can
increase the affinity to IDL particles [12]. In the presents
study, RemL-C was significantly associated with IDL but
RLP-C was not. It may be clinically important to know the
association of remnant lipoprotein cholesterol (RemL-C)
to IDL-cholesterol, because increased IDL-cholesterol lev-
els have been found to be associated with the incidence of
cardiovascular diseases in epidemiological studies [16-
18]. However, the RemL-C assay is prone to overestimate
remnant lipoprotein cholesterol levels in comparison
with RLP-C assay as shown in Figure 2. In addition to
increased affinity to IDL by POE-POB, the affinity to chy-
lomicron remnant is also enhanced by phospholipase D.
For that reason, RemL-C values may tend to be higher
than RLP-C values.
HPLC chromatograms of lipoproteins from the discrepant  samples Figure 3
HPLC chromatograms of lipoproteins from the dis-
crepant samples. Upper and lower panels indicate the 
HPLC lipoprotein chromatograms of the samples with 
RemL-C value < RLP-C value and with RemL-C value > RLP-
C value, respectively. CM means chylomicron.
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Bland & Altman analysis for data validation between RemL-C  and RLP-C Figure 2
Bland & Altman analysis for data validation between 
RemL-C and RLP-C. A and B indicate RemL-C and RLP-C 
value, respectively. Namely, X-axis shows RemL-C value + 
RLP-C value)/2, and Y-axis means RemL-C value – RLP-C 
value. The Bland & Altman analysis between RemL-C and 
RLP-C showed a significant proportional error (r = 0.558, p 
< 0.0001), implicating that RemL-C values are likely to be sig-
nificantly higher than RLP-C values.
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Conclusion
In conclusion, these results suggest that there is generally
a significant correlation between RemL-C, a novel homog-
enous assay and RLP-C, a conventional immunosepara-
tion method. However, RemL-C assay is likely to reflect
IDL more closely than RLP-C. Because of homogenous
simple method as opposed to RLP-C, RemL-C assay may
be useful for screening individuals with increased IDL,
potent atherogenic remnant lipoprotein although the
modest overestimation of remnant lipoprotein choles-
terol levels by RemL-C assay remains to be resolved.
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